Ligands with its PDB code and its tanimoto calculated from the molecule, present in the database, which has for MMscode: MMs00003104
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
| Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
|---|---|---|---|---|---|
| Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
GNT | (-)-GALANTHAMINE | A | 1DX6 | 0.72 |  |
| GNT | (-)-GALANTHAMINE | A | 1QTI | 0.72 | |
| GNT | (-)-GALANTHAMINE | A,B,C,D,E | 2PH9 | 0.72 | |
| GNT | (-)-GALANTHAMINE | A,B | 1W76 | 0.72 | |
| GNT | (-)-GALANTHAMINE | A | 1W6R | 0.72 | |
SAF | 3-[(1S)-1-(DIMETHYLAMINO)ETHYL]PHENOL | A | 1GQR | 0.8 | |
| SAF | 3-[(1S)-1-(DIMETHYLAMINO)ETHYL]PHENOL | A | 1GQS | 0.8 | |
BP7 | 1,1'-BIPHENYL-3,4-DIOL | A | 2EI0 | 0.73 | |
A48 | 4-[(DIMESITYLBORYL)(2,2,2-TRIFLUOROETHYL)AMINO]PHENOL | A,B | 2Q6J | 0.7 | |
MDW | (1R)-N,6-DIHYDROXY-7-METHOXY-2- [(4-METHOXYPHENYL)SULFONYL]-1,2,3,4- TETRAHYDROISOQUINOLINE-1-CARBOXAMIDE | A | 2DDY | 0.72 | |
BPY | BIPHENYL-2,3-DIOL | A | 1KMY | 0.72 | |
| BPY | BIPHENYL-2,3-DIOL | B | 1KW8 | 0.72 | |
| BPY | BIPHENYL-2,3-DIOL | A | 2EI3 | 0.72 | |
| BPY | BIPHENYL-2,3-DIOL | A | 1EIR | 0.72 | |
| BPY | BIPHENYL-2,3-DIOL | B | 1KW6 | 0.72 | |
| BPY | BIPHENYL-2,3-DIOL | B | 1KWC | 0.72 | |
| BPY | BIPHENYL-2,3-DIOL | B | 1KW9 | 0.72 | |
MOI | (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A- HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2- E]ISOQUINOLINE-7,9-DIOL | H,L | 1Q0Y | 0.73 | |
TY3 | 3-HYDROXY-L-TYROSINE | A,B | 2VH3 | 0.71 | |
PTI | 2-PHENYL-1-[4-(2-PIPERIDIN-1-YL- ETHOXY)-PHENYL]-1,2,3,4-TETRAHYDRO- ISOQUINOLIN-6-OL | A | 1UOM | 0.73 | |
BM4 | 3-[(3R)-3-ethyl-1-{9-[(3S)-3-ethyl- 3-(3-hydroxyphenyl)azepan-1-yl]nonyl}azepan- 3-yl]phenol | X | 2W6C | 0.76 | |
REN | (S)-reticuline | A | 3FWA | 0.92 | |
| REN | (S)-reticuline | A | 3D2D | 0.92 | |
3QC | (4R)-4-(3-HYDROXYPHENYL)-N,N,7,8- TETRAMETHYL-3,4-DIHYDROISOQUINOLINE- 2(1H)-CARBOXAMIDE | A,B | 2FME | 0.83 | |
ALE | L-EPINEPHRINE | A | 3PAH | 0.72 | |
| ALE | L-EPINEPHRINE | A | 2HKK | 0.72 | |
LDP | L-DOPAMINE | A,B | 2A3R | 0.74 | |
| LDP | L-DOPAMINE | A | 5PAH | 0.74 | |
| LDP | L-DOPAMINE | A,B | 2QMZ | 0.74 | |
| LDP | L-DOPAMINE | A,B | 2VQ5 | 0.74 | |
Y13 | (2E)-3-(3,4-DIHYDROXYPHENYL)-N- [2-(4-HYDROXYPHENYL)ETHYL]ACRYLAMIDE | A | 2EW6 | 0.75 | |
AEJ | (1S)-1-{4-[(9AR)-OCTAHYDRO-2H-PYRIDO[1,2- A]PYRAZIN-2-YL]PHENYL}-2-PHENYL- 1,2,3,4-TETRAHYDROISOQUINOLIN-6- OL | A,B,C,D | 1XQC | 0.78 | |
RHP | (3R)-3-(PROP-2-YNYLAMINO)INDAN- 5-OL | A,B | 1S3E | 0.74 | |
A88 | (5R,6R)-2,4-BIS-(4-HYDROXY-3-METHOXYBENZYL)- 1,5-DIBENZYL-3-OXO-6-HYDROXY-1,2,4- TRIAZACYCLOHEPTANE | A | 1PRO | 0.71 | |
SLX | (13aS)-3,10-dimethoxy-5,8,13,13a- tetrahydro-6H-isoquino[3,2-a]isoquinoline- 2,9-diol | A | 3FW9 | 0.89 | |
YTT | (3S,6S)-3,6-bis(4-hydroxybenzyl)piperazine- 2,5-dione | A | 3G5H | 0.7 | |
ETC | (R,R)-5,11-CIS-DIETHYL-5,6,11,12- TETRAHYDROCHRYSENE-2,8-DIOL | A,B | 1L2I | 0.71 | |
| ETC | (R,R)-5,11-CIS-DIETHYL-5,6,11,12- TETRAHYDROCHRYSENE-2,8-DIOL | A,B | 1L2J | 0.71 | |
HXS | 4-[(1R,2S)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol | A,B | 3CV6 | 0.7 | |
RM2 | 4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN | A,B | 2C66 | 0.72 | |
DPD | A,B | 1QIW | 0.73 | | |
| DPD | A | 1QIV | 0.73 | | |
D1N | NAPHTHALENE-1,2-DIOL | A | 2EI1 | 0.72 | |
DAH | 3,4-DIHYDROXYPHENYLALANINE | A,B | 1RNR | 0.71 | |
| DAH | 3,4-DIHYDROXYPHENYLALANINE | A | 6PAH | 0.71 | |
| DAH | 3,4-DIHYDROXYPHENYLALANINE | A,B | 1IVV | 0.71 | |
MA0 | (1R)-6-HYDROXY-N-METHYL-N-[(1Z)- PROP-2-EN-1-YLIDENE]INDAN-1-AMINIUM | A,B | 2C64 | 0.76 | |
OI1 | 3-(4-HYDROXYBENZYL)-2-[1-({[2-(4- HYDROXYPHENYL)ETHYL]AMINO}CARBONYL)BUTYL]- 4-OXO-3,6,11,11A-TETRAHYDRO-4H- PYRAZINO[1,2-B]ISOQUINOLIN-2-IUM- 1-OLATE | A,B | 1Q9D | 0.7 | |